Healthcare resource utilization and costs in working-age patients with high-risk atherosclerotic cardiovascular disease: findings from a multi-employer claims database

References

• Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. J Am Coll Cardiol 2014;63:2889-934
   Google Scholar
• Mendis S, Puska P, Norrving B, eds. Global atlas on cardiovascular disease prevention and control. Geneva; World Health Organization, 2011
   Google Scholar
• Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics–2014 update: a report from the American Heart Association. Circulation 2014;129:e28-292
   PubMed Web of Science ®Google Scholar
• Sampson UK, Fazio S, Linton MF. Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges. Curr Atheroscler Rep 2012;14:1-10
   PubMed Web of Science ®Google Scholar
• Mora S, Wenger NK, DeMicco DA, et al. Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: The Treating to New Targets (TNT) Study. Circulation 2012;125:1979-87
   PubMed Web of Science ®Google Scholar
• Odden MC, Coxson PG, Moran A, et al. The impact of the aging population on coronary heart disease in the United States. Am J Med 2011;124:827-33
   PubMed Web of Science ®Google Scholar
• Mahoney EM, Wang K, Keo HH, et al. Vascular hospitalization rates and costs in patients with peripheral artery disease in the United States. Circ Cardiovasc Qual Outcomes 2010;3:642-51
   PubMed Web of Science ®Google Scholar
• Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics–2012 update: a report from the American Heart Association. Circulation 2012;125:e2-220
   PubMed Web of Science ®Google Scholar
• Turpie AGG. Burden of disease: medical and economic impact of acute coronary syndromes. Am J Manag Care 2006;12(16 Suppl):S430-4
   PubMed Web of Science ®Google Scholar
• Hyre AD, Muntner P, Menke A, et al. Trends in ATP-III-defined high blood cholesterol prevalence, awareness, treatment and control among U.S. adults. Ann Epidemiol 2007;17:548-55
   PubMed Web of Science ®Google Scholar
• de Rojas FD, De Frutos T, Ponte A, et al. Coronary heart disease and dyslipidemia: a cross-sectional evaluation of prevalence, current treatment, and clinical control in a large cohort of Spanish high-risk patients: the PRINCEPS study. Prev Cardiol 2009;12:65-71
   PubMedGoogle Scholar
• Muller-Nordhorn J, Englert H, Wegscheider K, et al. Productivity loss as a major component of disease-related costs in patients with hypercholesterolemia in Germany. Clin Res Cardiol 2008;97:152-9
   PubMed Web of Science ®Google Scholar
• Zhao Z, Zhu Y, Fang Y, et al. Demographic and clinical characteristics and treatment of cardiovascular risk factors in working age patients with high-risk vascular disease: findings from a multi-employer U.S. claims data base. Presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual International Meeting, New Orleans, LA, May 2013
   Google Scholar
• Kannel WB. Risk factors for atherosclerotic cardiovascular outcomes in different arterial territories. J Cardiovasc Risk 1994;1:333-9
   PubMedGoogle Scholar
• Lahoz C, Mostaza JM. Atherosclerosis as a systemic disease. Rev Esp Cardiol 2007;60:184-95
   PubMed Web of Science ®Google Scholar
• Shigematsu H, Komori K, Tanemoto K, et al. Clopidogrel for Atherothrombotic Event Management in Patients with Peripheral Arterial Disease (COOPER) Study: safety and efficacy of clopidogrel versus ticlopidine in Japanese patients. Ann Vasc Dis 2012;5:364-75
   Google Scholar
• Viles-Gonzalez JF, Fuster V, Badimon JJ. Atherothrombosis: a widespread disease with unpredictable and life-threatening consequences. Eur Heart J 2004;25:1197-207
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. J Am Med Assoc 2006;295:180-9
   PubMed Web of Science ®Google Scholar
• National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Circulation 2002;106:3143-421
   PubMed Web of Science ®Google Scholar
• Reiner X, Catapano AL, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32:1769-818
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Eagle KA, Ohman EM, et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. J Am Med Assoc 2010;304:1350-7
   PubMed Web of Science ®Google Scholar
• Fox CS, Coady S, Sorlie PD, et al. Increasing cardiovascular disease burden due to diabetes mellitus. The Framingham Heart Study. Circulation 2007;115:1544-50
   PubMed Web of Science ®Google Scholar
• Fox CS, Coady S, Sorlie PD, et al. Trends in cardiovascular complications of diabetes. J Am Med Assoc 2004;292:2495-9
   PubMed Web of Science ®Google Scholar
• Lopez-de-Andres A, Hernández-Barrera V, Carrasco-Garrido P, et al. Trends of hospitalizations, fatality rate and costs for acute myocardial infarction among Spanish diabetic adults, 2001-2006. BMC Health Serv Res 2010;10:59
   PubMedGoogle Scholar
• Fang J, Alderman MH. Impact of the increasing burden of diabetes on acute myocardial infarction in New York City: 1990–2000. Diabetes 2006;55:768-73
   PubMed Web of Science ®Google Scholar
• American Diabetes Association (ADA). Standards of medical care in diabetes – 2013. Diabetes Care 2013;36(Suppl 1):S11-66
   PubMedGoogle Scholar
• Jacobson TA, Ito MK, Maki KC, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 – executive summary. J Clin Lipidol 2014;8:473-88
   PubMed Web of Science ®Google Scholar
• Jellinger PS, Smith DA, Mehta AE, et al. American Association of Clinical Endocrinologists’ guidelines for management of dyslipidemia and prevention of atherosclerosis. Endocr Pract 2012;18(1 Suppl):1-78
   Google Scholar
• Hansen LG, Chang S. White Paper Health Research Data for the Real World: The MarketScan Databases. Truven Health Analytics. 2013
   Google Scholar
• Lassman D, Hartman M, Washington B, et al. US health spending trends by age and gender: Selected years 2002–10. Health Affairs 2014;33:815-22
   Web of Science ®Google Scholar
• Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics—2015 update. A report from the American Heart Association. Circulation 2015;131:e29-322
   PubMed Web of Science ®Google Scholar
• Zhao Z, Zhu B, Anderson J, et al. Resource utilization and healthcare costs for acute coronary syndrome patients with and without diabetes mellitus. J Med Econ 2010;13:748-59
   PubMedGoogle Scholar
• Malone M, Lau NS, White J, et al. The effect of diabetes mellitus on costs and length of stay in patients with peripheral arterial disease undergoing vascular surgery. Eur J Vasc Endovasc Surg 2014;48:447-51
   PubMed Web of Science ®Google Scholar
• Straka RJ, Liu LZ, Girase PS, et al. Incremental cardiovascular costs and resource use associated with diabetes: an assessment of 29,863 patients in the US managed-care setting. Cardiovasc Diabetol 2009;8:53
   PubMed Web of Science ®Google Scholar
• Bramkamp M, Radovanovic D, Erne P, et al. Determinants of costs and the length of stay in acute coronary syndromes: a real life analysis of more than 10,000 patients. Cardiovasc Drugs Ther 2007;21:389-98
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. J Am Coll Cardiol 2004;44:720-32
   PubMed Web of Science ®Google Scholar
• National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421
   PubMed Web of Science ®Google Scholar